Baillie Gifford
One of the world's largest independent investment management firms. Long-term growth investor with significant holdings in healthcare and life sciences companies globally, including major positions in Moderna and other biotech leaders.
Location
Edinburgh, UK
Founded
1908
AUM
$300B+
Investment Range
$50M - $500M
Portfolio Companies
1
Focus
generalist
Fund Stages
series-c, growth
Investment Thesis
Baillie Gifford takes an extremely long-term investment approach (typically 5-10+ years), focusing on identifying companies with potential for transformational growth. In healthcare and life sciences, they invest in companies developing breakthrough therapies and diagnostic technologies that can meaningfully improve patient outcomes at scale.
Team
Partners / Managing Directors (Health & Bio Focus)
- Julia Angeles - Partner, Healthcare
- Gary Robinson - Partner
Other Key Team Members
- Partnership structure with over 50 partners across the firm
Focus Areas
- Healthcare Technology
- Biotechnology
- Therapeutics
- Genomics
- Diagnostics
- Medical Devices
- Long-term Growth Investing
Notable Exits
- Moderna - Major shareholder during COVID-19 vaccine development
- Tempus AI - Series E and Series F investor
- Illumina - Long-term shareholder
- 10x Genomics - Growth investor
Sources
- https://www.bailliegifford.com
- https://www.bailliegifford.com/team
- https://www.sec.gov/cgi-bin/browse-edgar (13F filings)
- Company shareholder reports
Portfolio Companies
| Name | Location | Founded | Categories |
|---|---|---|---|
| Tempus AI | Chicago, Illinois, USA | 2015 | genomics-sequencingai-drug-discovery+4 |